Programación y gestión de redes de notas via Internet I

Este trabajo presenta los desarrollos llevados a cabo en CIMNE en la programación y gestión de redes de motas utilizando Internet. El trabajo se enmarca dentro de la línea de I+D de CIMNE en el estudio, desarrollo y aplicación de redes de sensores inteligentes sin hilos en diversos ámbitos de la ingeniería. En las referencias [(1-3)] se describen los resultados de investigaciones anteriores del equipo de CIMNE sobre el tema. El trabajo se ha llevado a cabo en el marco de las actividades del proyecto "Desarrollo de tecnologías para investigación y gestión de procesos constructivos utilizando redes de sensores sin hilos.(PROSENSOR)" financiado por el programa PROFIT del Ministerio de Educación y Ciencia. El proyecto se inició en Noviembre de 2005 y su finalización está prevista en Diciembre, 2007. Los autores agradecen a la empresa Sensoria S.A., el asesoramiento y colaboración en la realización del trabajo.Preprin

Plataforma WSN/NIMS III: programación básica de motas

Preprin

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Plataforma WSN/NIMS I

Preprin

Plataforma WSN/NIMS II: primeras experiencias en CIMNE

Preprin